An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis

Neurobiology of Disease

Volumn 37, Issue 1, 2010, Pages 166-176

  Loria F ^a   Petrosino, S ^b   Hernangomez M ^a   Mestre, L ^a   Spagnolo, A ^a   Correa, F ^a   Di Marzo, V ^b   Docagne, F ^a,c   Guaza, C ^a  

^a INSTITUTO CAJAL   (Spain)

^b CNR   (Italy)

^c INSERM   (France)

Author keywords

(Endo)cannabinoids; Excitotoxicity; Multiple sclerosis; TMEV; UCM707

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; N (3 FURYLMETHYL)ARACHIDONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VESICULAR GLUTAMATE TRANSPORTER 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EXCITOTOXICITY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE SCLEROSIS; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN INDUCTION; RECEPTOR UPREGULATION;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; ARACHIDONIC ACIDS; ASTROCYTES; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; EXCITATORY AMINO ACID TRANSPORTER 2; FEMALE; FURANS; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MULTIPLE SCLEROSIS; N-METHYLASPARTATE; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; POLYUNSATURATED ALKAMIDES; PPAR GAMMA; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 70449518017     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.09.020     Document Type: Article

References (53)

1. Arevalo-Martin A., et al. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 23 (2003) 2511-2516
2. Barten D.M., and Albright C.F. Therapeutic strategies for Alzheimer's disease. Mol. Neurobiol. 37 (2008) 171-186
3. Beltramo M., and Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. NeuroReport 11 (2000) 1231-1235
4. Bisogno T., and Di Marzo V. Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. Pharmacol. Res. 56 (2007) 428-442
5. Bouaboula M., et al. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol. 517 (2005) 174-181
6. Brown A.J. Novel cannabinoid receptors. Br. J. Pharmacol. 152 (2007) 567-575
7. Centonze D., et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 130 (2007) 2543-2553
8. Centonze D., et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci. 29 (2009) 3442-3452
9. Choi D.W. Excitotoxic cell death. J. Neurobiol. 23 (1992) 1261-1276
10. Croxford J.L., et al. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J. Neuroimmunol. 193 (2008) 120-129
11. de Lago E., et al. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur. Neuropsychopharmacol. 16 (2006) 7-18
12. De Petrocellis L., et al. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 506 (2001) 253-256
13. Di Marzo V., and Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol. 18 (2007) 129-140
14. Di Marzo V., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
15. Di Marzo V., et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 358 (2001) 249-255
16. Docagne F., et al. Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-beta 1 against NMDA-induced necrosis. Mol. Cell. Neurosci. 21 (2002) 634-644
17. Docagne F., et al. Excitotoxicity in a chronic model of multiple sclerosis: neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol. Cell. Neurosci. 34 (2007) 551-561
18. Docagne F., et al. Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opin. Ther. Targets. 12 (2008) 185-195
19. Fernandez-Lopez D., et al. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr. Res. 60 (2006) 169-173
20. Fu J., et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425 (2003) 90-93
21. Gonsette R.E. Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis?. Mult. Scler. 14 (2008) 22-34
22. Hillard C.J. Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr. Pharm. Des. 14 (2008) 2347-2361
23. Ho W.S., et al. 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol. 155 (2008) 837-846
24. Hoyte L., et al. The rise and fall of NMDA antagonists for ischemic stroke. Curr. Mol. Med. 4 (2004) 131-136
25. Jonsson K.O., et al. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br. J. Pharmacol 133 (2001) 1263-1275
26. Jourdain P., et al. Glutamate exocytosis from astrocytes controls synaptic strength. Nat. Neurosci 10 (2007) 331-339
27. Koh J.Y., and Choi D.W. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J. Neurosci. Methods 20 (1987) 83-90
28. Lastres-Becker I., et al. The endocannabinoid system and Huntington's disease. Curr. Drug Targets CNS Neurol. Disord. 2 (2003) 335-347
29. Lastres-Becker I., et al. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 19 (2005) 96-107
30. Lledo A., et al. Dexamethasone regulation of interleukin-1-receptors in the hippocampus of Theiler's virus-infected mice: effects on virus-mediated demyelination. Eur. J. Pharmacol. 372 (1999) 75-83
31. Loria F., et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci. 28 (2008) 633-641
32. Marsicano G., et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003) 84-88
33. McGavern D.B., et al. Quantitation of spinal cord demyelination, remyelination, atrophy, and axonal loss in a model of progressive neurologic injury. J. Neurosci. Res. 58 (1999) 492-504
34. Mestre L., et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 92 (2005) 1327-1339
35. Molina-Holgado F., et al. Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol. Cell. Neurosci. 28 (2005) 189-194
36. Navarrete M., and Araque A. Endocannabinoids mediate neuron-astrocyte communication. Neuron 57 (2008) 883-893
37. Ohgoh M., et al. Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 125 (2002) 170-178
38. Ortega-Gutierrez S., et al. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J. 19 (2005) 1338-1340
39. O'Sullivan S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol. 152 (2007) 576-582
40. Ouardouz M., et al. Glutamate receptors on myelinated spinal cord axons. II. AMPA and GluR5 receptors. Ann. Neurol. 65 (2009) 160-166
41. Ouardouz M., et al. Glutamate receptors on myelinated spinal cord axons. I. GluR6 kainate receptors. Ann. Neurol. 65 (2009) 151-159
42. Panikashvili D., et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413 (2001) 527-531
43. Pawlak J., et al. Regulation of glutamate transporter GLAST and GLT-1 expression in astrocytes by estrogen. Brain Res. Mol. Brain Res. 138 (2005) 1-7
44. Pitt D., et al. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6 (2000) 67-70
45. Ramirez B.G., et al. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25 (2005) 1904-1913
46. Rockwell C.E., et al. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol. Pharmacol. 70 (2006) 101-111
47. Romera C., et al. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. J. Cereb. Blood Flow Metab. 27 (2007) 1327-1338
48. Rose K., et al. Cytotoxicity in murine neocortical cell culture. In: Tyson C.A., and Frazier J.M. (Eds). Methods in Neurotoxicology (1993), Academic Press, San Diego 46-60
49. Sagredo O., et al. Cannabinoids and neuroprotection in basal ganglia disorders. Mol. Neurobiol. 36 (2007) 82-91
50. Shaw P.J., and Ince P.G. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J. Neurol. 244 Suppl. 2 (1997) S3-S14
51. Smith T., et al. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6 (2000) 62-66
52. Sun Y., and Bennett A. Cannabinoids: a new group of agonists of PPARs. PPAR Res. 2007 (2007) 23513
53. Tsunoda I., et al. Axonal injury heralds virus-induced demyelination. Am. J. Pathol. 162 (2003) 1259-1269